Inovio Pharmaceuticals Stock Fundamentals
| INO Stock | USD 4.07 0.01 0.25% |
Inovio Pharmaceuticals fundamentals help investors to digest information that contributes to Inovio Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Inovio Stock. The fundamental analysis module provides a way to measure Inovio Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inovio Pharmaceuticals stock.
At this time, Inovio Pharmaceuticals' Total Other Income Expense Net is very stable compared to the past year. As of the 24th of November 2024, Selling General Administrative is likely to grow to about 50 M, while Depreciation And Amortization is likely to drop about 2.4 M. Inovio | Select Account or Indicator |
Inovio Pharmaceuticals Company Operating Margin Analysis
Inovio Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Inovio Pharmaceuticals Operating Margin | (329.46) % |
Most of Inovio Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inovio Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Inovio Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Inovio Pharmaceuticals has an Operating Margin of -329.4587%. This is much higher than that of the Biotechnology sector and 193.98% higher than that of the Health Care industry. The operating margin for all United States stocks is notably higher than that of the company.
Inovio Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Inovio Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Inovio Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inovio Pharmaceuticals competition to find correlations between indicators driving Inovio Pharmaceuticals's intrinsic value. More Info.Inovio Pharmaceuticals is rated fourth overall in return on equity category among its peers. It is rated fifth overall in return on asset category among its peers . At this time, Inovio Pharmaceuticals' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inovio Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Inovio Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inovio Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inovio Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Inovio Pharmaceuticals by comparing valuation metrics of similar companies.Inovio Pharmaceuticals is currently under evaluation in operating margin category among its peers.
Inovio Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inovio Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inovio Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Inovio Fundamentals
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (329.46) % | ||||
| Current Valuation | 33.61 M | ||||
| Shares Outstanding | 26.1 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 33.51 % | ||||
| Number Of Shares Shorted | 3.5 M | ||||
| Price To Earning | (5.43) X | ||||
| Price To Book | 1.44 X | ||||
| Price To Sales | 179.48 X | ||||
| Revenue | 832.01 K | ||||
| Gross Profit | (177.39 M) | ||||
| EBITDA | (130.39 M) | ||||
| Net Income | (135.12 M) | ||||
| Cash And Equivalents | 348.13 M | ||||
| Cash Per Share | 1.40 X | ||||
| Total Debt | 30.21 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | 5.15 X | ||||
| Cash Flow From Operations | (124.37 M) | ||||
| Short Ratio | 11.22 X | ||||
| Earnings Per Share | (4.43) X | ||||
| Target Price | 10.67 | ||||
| Number Of Employees | 127 | ||||
| Beta | 0.83 | ||||
| Market Capitalization | 106.23 M | ||||
| Total Asset | 172.94 M | ||||
| Retained Earnings | (1.62 B) | ||||
| Working Capital | 110.54 M | ||||
| Current Asset | 171.85 M | ||||
| Current Liabilities | 31.47 M | ||||
| Net Asset | 172.94 M |
About Inovio Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inovio Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inovio Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inovio Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 24.9 K | 23.6 K | |
| Total Revenue | 832 K | 790.4 K | |
| Cost Of Revenue | 3.5 M | 3.3 M | |
| Stock Based Compensation To Revenue | 13.31 | 12.64 | |
| Sales General And Administrative To Revenue | 57.19 | 60.05 | |
| Research And Ddevelopement To Revenue | 106.34 | 111.66 | |
| Capex To Revenue | 0.39 | 0.29 | |
| Revenue Per Share | 0.04 | 0.04 | |
| Ebit Per Revenue | (162.53) | (154.40) |
Check out Inovio Pharmaceuticals Piotroski F Score and Inovio Pharmaceuticals Altman Z Score analysis. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share 0.025 | Quarterly Revenue Growth (0.55) | Return On Assets (0.40) | Return On Equity (0.91) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.